Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Clin Neurophysiol ; 123(5): 902-9, 2012 May.
Artigo em Inglês | MEDLINE | ID: mdl-21996001

RESUMO

OBJECTIVE: To investigate changes in cortical excitability and short-term synaptic plasticity we delivered 5 Hz repetitive transcranial magnetic stimulation (rTMS) over the primary motor cortex in 11 patients with mild-to-moderate Alzheimer's disease (AD) before and after chronic therapy with rivastigmine. METHODS: Resting motor threshold (RMT), motor evoked potential (MEP), cortical silent period (CSP) after single stimulus and MEP facilitation during rTMS trains were tested three times during treatment. All patients underwent neuropsychological tests before and after receiving rivastigmine. rTMS data in patients were compared with those from age-matched healthy controls. RESULTS: At baseline, RMT was significantly lower in patients than in controls whereas CSP duration and single MEP amplitude were similar in both groups. In patients, rTMS failed to induce the normal MEP facilitation during the trains. Chronic rivastigmine intake significantly increased MEP amplitude after a single stimulus, whereas it left the other neurophysiological variables studied unchanged. No significant correlation was found between patients' neuropsychological test scores and TMS measures. CONCLUSIONS: Chronic treatment with rivastigmine has no influence on altered cortical excitability and short-term synaptic plasticity as tested by 5 Hz-rTMS. SIGNIFICANCE: The limited clinical benefits related to cholinesterase inhibitor therapy in patients with AD depend on factors other than improved plasticity within the cortical glutamatergic circuits.


Assuntos
Doença de Alzheimer , Potencial Evocado Motor/efeitos dos fármacos , Córtex Motor/efeitos dos fármacos , Fenilcarbamatos/farmacologia , Fenilcarbamatos/uso terapêutico , Estimulação Magnética Transcraniana , Idoso , Idoso de 80 Anos ou mais , Doença de Alzheimer/tratamento farmacológico , Doença de Alzheimer/patologia , Doença de Alzheimer/fisiopatologia , Análise de Variância , Estudos de Casos e Controles , Eletromiografia , Feminino , Lateralidade Funcional/efeitos dos fármacos , Humanos , Estudos Longitudinais , Masculino , Entrevista Psiquiátrica Padronizada , Músculo Esquelético/efeitos dos fármacos , Fármacos Neuroprotetores/farmacologia , Fármacos Neuroprotetores/uso terapêutico , Tempo de Reação , Rivastigmina
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...